Indivior Pharmaceuticals, Inc. (INDV) FY2025 10-K Annual Report
Indivior Pharmaceuticals, Inc. (INDV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Indivior Pharmaceuticals, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
- • Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
- • Increasing regulatory focus on data privacy and security with rising investments and risks related to AI integration and cyber threats
- • Foreign exchange risk heightened by 85% U.S. revenue concentration in 2025 and limited active currency hedging strategy
- • Noteworthy: AI-related risks and vendor use of generative AI highlighted as emerging compliance and security challenges
Management Discussion & Analysis
- • Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
- • No profitability or operating margin figures disclosed in the text
- • No segment performance data provided
- • No cash flow, capital allocation, buybacks, dividends, or capex details included
- • No forward-looking guidance or risk outlook mentioned in the provided section
Risk Factors
- • FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
- • Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
- • Single or dual sourcing for most raw materials and APIs risks supply interruption with average 36-month technology transfer delay to new suppliers
- • 2023 entry of a competitor’s extended-release injectable buprenorphine challenges SUBLOCADE’s market share in once-monthly OUD treatment
- • Leveraged balance sheet and term loan covenants constraining financial flexibility amid potential revenue declines
Indivior Pharmaceuticals, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$1.2B
▲ +4.3% YoY
Net Income
$210M
▲ +10400.0% YoY
Gross Margin
80.2%
▼ -33bp YoY
Operating Margin
21.1%
▲ +1845bp YoY
Net Margin
16.9%
▲ +1678bp YoY
ROE
-214.3%
▼ -21371bp YoY
Total Assets
$1.2B
▼ -8.9% YoY
EPS (Diluted)
$1.64
▲ +8100.0% YoY
Operating Cash Flow
-$27M
▼ -175.0% YoY
Source: XBRL data from Indivior Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Indivior Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.